In the era of immunotherapy, ICIs, including PD-1/PD-L1 inhibitors, can block negative regulatory signaling pathways, leading to activation of T cells from an exhausted status, and then promote subsequent T cell-mediated cancer cell killing. Here, PDCD1 is linked to cancer.